医渡科技(02158)今天盘中大涨5%,引起了市场广泛关注。公司在助力我国干细胞疗法领域取得重大突破的同时,业绩表现也十分亮眼。
根据消息,由医渡科技参与二期、三期临床开发的"艾米迈托赛注射液"获批上市,这是我国首款干细胞治疗药品。医渡科技作为项目的关键合作伙伴,为该药物获批做出了重大贡献,推动了我国干细胞疗法在多个适应症上的临床探索,是干细胞疗法领域的里程碑。
除了助力科研创新,医渡科技在业绩方面表现也十分亮眼。公司2025财年上半年的业绩报告显示,在经历连年亏损后,公司盈利情况出现扭转,上半年调整后盈利超过2700万元人民币,业绩水平已经接近2024财年全年的水平,创下历史同期最好业绩。这有力支持了公司股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.